N-terminal mutations activate the leukemogenic potential of the myristoylated form of c-abl
about
The complete coding sequence of arg defines the Abelson subfamily of cytoplasmic tyrosine kinasesThe product of the cbl oncogene forms stable complexes in vivo with endogenous Crk in a tyrosine phosphorylation-dependent mannerMolecular identification of a major palmitoylated erythrocyte membrane protein containing the src homology 3 motifDirect interaction of Jak1 and v-Abl is required for v-Abl-induced activation of STATs and proliferationAhi-1, a novel gene encoding a modular protein with WD40-repeat and SH3 domains, is targeted by the Ahi-1 and Mis-2 provirus integrationsCharacterization of a novel member of the DOK family that binds and modulates Abl signalingActivation of murine c-abl protooncogene: effect of a point mutation on oncogenic activationAssociation of the v-crk oncogene product with phosphotyrosine-containing proteins and protein kinase activityEps8, a substrate for the epidermal growth factor receptor kinase, enhances EGF-dependent mitogenic signalsCharacterization of a guanine nucleotide dissociation stimulator for a ras-related GTPaseThe PAG gene product, a stress-induced protein with antioxidant properties, is an Abl SH3-binding protein and a physiological inhibitor of c-Abl tyrosine kinase activityMutagenic analysis of the roles of SH2 and SH3 domains in regulation of the Abl tyrosine kinaseTwo species of human CRK cDNA encode proteins with distinct biological activitiesc-ABL tyrosine kinase activity is regulated by association with a novel SH3-domain-binding proteinThe amphiphysin-like protein 1 (ALP1) interacts functionally with the cABL tyrosine kinase and may play a role in cytoskeletal regulationWAVE2 regulates epithelial morphology and cadherin isoform switching through regulation of Twist and AblCrystal structure of the SH3 domain in human Fyn; comparison of the three-dimensional structures of SH3 domains in tyrosine kinases and spectrinA conserved proline-rich region of the Saccharomyces cerevisiae cyclase-associated protein binds SH3 domains and modulates cytoskeletal localization.SDC25, a CDC25-like gene which contains a RAS-activating domain and is a dispensable gene of Saccharomyces cerevisiae.Proline-rich sequences that bind to Src homology 3 domains with individual specificitiesLoss of expression of human spectrin src homology domain binding protein 1 is associated with 10p loss in human prostatic adenocarcinomaThe cytostatic function of c-Abl is controlled by multiple nuclear localization signals and requires the p53 and Rb tumor suppressor gene productsTwo distinct phosphorylation pathways have additive effects on Abl family kinase activationProduction of high-titer helper-free retroviruses by transient transfectionSH3 domains: modules of protein-protein interactions.Differences in structural elements of Bcr-Abl oncoprotein isoforms in Chronic Myelogenous Leukemia.A versatile approach to transform low-affinity peptides into protein probes with cotranslationally expressed chemical cross-linker.A crucial role in cell spreading for the interaction of Abl PxxP motifs with Crk and Nck adaptors.Bcr-Abl with an SH3 deletion retains the ability To induce a myeloproliferative disease in mice, yet c-Abl activated by an SH3 deletion induces only lymphoid malignancyThe murine AIDS virus Gag precursor protein binds to the SH3 domain of c-AblLckBP1, a proline-rich protein expressed in haematopoietic lineage cells, directly associates with the SH3 domain of protein tyrosine kinase p56lck.3BP-1, an SH3 domain binding protein, has GAP activity for Rac and inhibits growth factor-induced membrane ruffling in fibroblasts.Hormone-conditional transformation by fusion proteins of c-Abl and its transforming variantsBoth the SH2 and SH3 domains of human CRK protein are required for neuronal differentiation of PC12 cells.En bloc substitution of the Src homology region 2 domain activates the transforming potential of the c-Abl protein tyrosine kinase.The SH2- and SH3-containing Nck protein transforms mammalian fibroblasts in the absence of elevated phosphotyrosine levels.Biological and biochemical activity of v-Crk chimeras containing the SH2/SH3 regions of phosphatidylinositol-specific phospholipase C-gamma and Src.Evidence for regulation of the human ABL tyrosine kinase by a cellular inhibitorBCR first exon sequences specifically activate the BCR/ABL tyrosine kinase oncogene of Philadelphia chromosome-positive human leukemias.Identification of domains of the v-crk oncogene product sufficient for association with phosphotyrosine-containing proteins.
P2860
Q24292892-AA6F19E9-7B37-4153-AE89-302D07B4AC80Q24310761-07AEB187-0319-4341-901F-0A6EB998A49DQ24321553-F62A7830-F6EA-48B0-BA10-E02B2B6CA657Q24522820-6CEED9B6-125E-4680-A862-74657C20394EQ24538391-464BA107-599D-4A98-934E-1D969BC4FBFCQ24554382-2407E2BF-46BE-444B-897E-CEC9AD3D54B2Q24557464-9805A4AC-CD41-4624-B20D-00CBD502B4F3Q24558728-13B6751E-689E-4214-A58F-88CA5D55A4D9Q24564389-19650C7C-948A-45CB-B462-BCA3AFE117B3Q24564827-4EDF0174-FDCE-4D95-BA40-6542D2A9E0BDQ24606662-225D04CA-3E4F-44ED-86CD-62794E1AA20BQ24612979-20FBED20-C3B3-49C2-9E96-2C80357AFA39Q24629936-2111600A-1984-42BA-A709-08D9956D41C6Q24647548-288F6CA6-A856-4476-842C-B3792545FA05Q24649024-C595D536-4C3D-4E04-A10E-9CF2545B6839Q27318554-907612A0-B459-4CE8-B90D-6EB8FD2306C9Q27729913-04F362DA-F4FF-4405-A0E7-032408075539Q27935759-3CB54946-F7EC-4A24-A878-EB1630F207FFQ27936218-886D49BA-7FE3-436A-A170-269510A79BE3Q28287774-6DE8D17A-290C-4467-AFAF-09749E88CF0EQ28367455-DAC10487-36D9-462F-B29C-B5A86BCE0F63Q28508496-F16702FB-CB15-415F-8CEC-5A30DA651E5CQ28585350-FA10D43B-CF3E-401C-9894-F4D3C983DD38Q29547802-007595AE-3A52-4AA0-9D93-4E01F0DEE830Q30008731-F485A44C-54E9-43C6-BF4E-79D531948205Q30009436-702FECF1-E788-4168-95E4-895F61D98757Q30156845-129AEEAC-81B7-48E1-9C80-4520D75A29F2Q30157529-5A1A1018-324D-4FA9-9DF3-AC4337716722Q30175351-87B028BD-B2A8-4CB8-AEAC-B810821B10FFQ30176596-8CA777C0-B6BF-42E9-8625-F0B30264C13EQ30193253-AD5C6E0B-85A1-4CD2-8C39-99C6FB340E78Q30193301-6FCEDB32-AD76-4AB0-A82F-A9BAB0A31853Q30194953-CE678A32-CEEE-4D34-BDAE-E1F72C17ED47Q30194957-F5621C76-EB7E-486A-A56A-390D2D8CE474Q30195067-B0A54325-31A0-441A-80C6-654F2D55B777Q30195199-06A9FA1C-B5F4-4269-9842-BB1B0B2DF099Q30195542-3E65A810-55C2-414C-9B10-109DB7CA0622Q30195654-EE13F545-AE95-4995-93AA-FB41C70D1B92Q30195698-AC1B33AE-1C45-4EE4-A6C4-0BFC1AC45554Q30195712-6E11DA7A-043C-4F27-90E7-0136DAF54018
P2860
N-terminal mutations activate the leukemogenic potential of the myristoylated form of c-abl
description
1989 nî lūn-bûn
@nan
1989 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
1989 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
1989年の論文
@ja
1989年論文
@yue
1989年論文
@zh-hant
1989年論文
@zh-hk
1989年論文
@zh-mo
1989年論文
@zh-tw
1989年论文
@wuu
name
N-terminal mutations activate ...... he myristoylated form of c-abl
@ast
N-terminal mutations activate ...... he myristoylated form of c-abl
@en
N-terminal mutations activate ...... e myristoylated form of c-abl.
@nl
type
label
N-terminal mutations activate ...... he myristoylated form of c-abl
@ast
N-terminal mutations activate ...... he myristoylated form of c-abl
@en
N-terminal mutations activate ...... e myristoylated form of c-abl.
@nl
prefLabel
N-terminal mutations activate ...... he myristoylated form of c-abl
@ast
N-terminal mutations activate ...... he myristoylated form of c-abl
@en
N-terminal mutations activate ...... e myristoylated form of c-abl.
@nl
P2860
P1433
P1476
N-terminal mutations activate ...... he myristoylated form of c-abl
@en
P2093
D Baltimore
P2860
P304
P407
P577
1989-02-01T00:00:00Z